Liangkun Guo, MD, PhD

Clinical development physician deeply involved in HS-10308 mental health development across Phase 2/3 studies. ▶ 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 * Contribute to protocol design and optimization, including population, endpoints, assessments, and safety monitoring. * Support development and execution of Medical Monitoring Plans and ongoing medical monitoring. * Review emerging safety and efficacy data to support benefit–risk assessment and study decisions. * Collaborate closely with cross-functional teams and investigators to address clinical and scientific issues.

中国药物滥用防治协会（CADAPT) 青年专家委员 Committee Member, Young Experts Committee, Chinese Association of Drug Abuse Prevention and Treatment（CADAPT)

China medical strategy, launch readiness, and evidence generation for KarXT and other psychiatry assets, with cross-functional contributions to clinical development. ▶ 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗔𝗳𝗳𝗮𝗶𝗿𝘀 • Led China medical strategy and launch-readiness activities for KarXT, translating global evidence and local unmet needs into medical priorities. • Drove the medical design of NEXT, a prospective multicenter real-world study of KarXT focused on functional recovery in schizophrenia. • Built scientific partnerships with leading psychiatrists and translated external insights into evidence-generation plans, medical education, and scientific communications. • Coordinated collaboration across BMS, HEOR, Epidemiology, PV, Regulatory, Clinical Operations, Biometrics, and Medical Writing. ▶ 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 • Contributed to protocol rationale, eligibility criteria, endpoint selection, safety surveillance, and exploratory analysis planning. • Supported China development strategy and CDE scientific discussions by integrating clinical, safety, and benefit–risk evidence. • Partnered with development and study teams on study start-up, investigator engagement, safety review, and data interpretation. • Contributed to development discussions across schizophrenia, Alzheimer’s disease–related agitation and psychosis, and bipolar disorder.

Regional medical affairs and field-based clinical development support for psychiatry pipeline assets. ▶ 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗔𝗳𝗳𝗮𝗶𝗿𝘀 • Delivered regional medical strategy and scientific engagement for psychiatry pipeline assets. • Managed relationships with psychiatrists and investigators through scientific exchange, advisory activities, congress engagement, and medical education. • Synthesized field insights on unmet needs, treatment practices, patient journeys, and evidence gaps to inform medical and development priorities. ▶ 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 • Provided China country input into clinical development plans for Phase 2 psychiatry programs, incorporating local unmet needs, standards of care, patient characteristics, regulatory considerations, investigator landscapes, and operational feasibility. • Participated in clinical development plan and asset strategy discussions with Clinical Research Physicians and global development teams, contributing perspectives on target populations, indication strategy, endpoints, comparators, recruitment, and evidence gaps. • Contributed to protocol review and study planning, including eligibility criteria, endpoint selection, safety considerations, site feasibility, and potential recruitment barriers. • Translated investigator feedback and China field insights into actionable recommendations for global development teams. • Connected investigators with cross-functional development teams and facilitated the resolution of clinical, scientific, and study-operational questions.

Research area: psychiatry clinical practice, genetics, and epigenetics, data science